Bridging Therapy for Severe Pain Management

Introduction to Bridging Therapy

The American College of Rheumatology recommends systemic glucocorticoids as adjunctive therapy to reduce severe pain and inflammation while waiting for DMARDs to take effect, providing rapid symptom relief within days 1, 2

Oral glucocorticoids are strongly recommended as temporary adjunctive treatment to control severe pain and inflammation during the DMARD initiation period, according to the European League Against Rheumatism 1, 2, 3
Glucocorticoids provide symptom relief within days, effectively "bridging" the 8-12 week gap until DMARDs like methotrexate reach therapeutic effect 4
The goal is temporary use only - glucocorticoids should be tapered and discontinued once DMARDs achieve adequate disease control, as suggested by the American College of Rheumatology 1, 2

Intra-articular glucocorticoid injections are conditionally recommended for relief of local symptoms in specific inflamed joints, according to the European League Against Rheumatism 1, 2, 3
These provide targeted pain relief without systemic exposure when only one or few joints are severely symptomatic 4

NSAIDs should be considered for symptomatic relief after evaluating gastrointestinal, renal, and cardiovascular risk factors, as recommended by the European League Against Rheumatism 3, 4
NSAIDs provide analgesia and anti-inflammatory effects but do not modify disease progression 3

The American College of Rheumatology recommends never delaying or substituting DMARD initiation - glucocorticoids are adjunctive only, not alternatives 1, 2
Methotrexate should be rapidly escalated to 25-30 mg/week within the first 8-12 weeks to achieve maximal therapeutic effect, as suggested by the European League Against Rheumatism 4

The American College of Rheumatology recommends planning for glucocorticoid discontinuation from the outset - these are not intended for long-term maintenance 1, 2
As DMARD efficacy develops (typically by 3-6 months), glucocorticoids should be tapered, according to the European League Against Rheumatism 1, 4

Disease activity should be assessed every 1-3 months during this critical period to ensure the treatment strategy is working, as recommended by the American College of Rheumatology 2, 4
If minimal improvement is not seen by 3 months, therapy adjustment is mandatory, according to the European League Against Rheumatism 4
The target is low disease activity or remission by 6 months, as suggested by the American College of Rheumatology 2, 4